Healthcare technology company FutureCure Health has raised ₹104 crore (about $11.5 million) in a funding round led by Carnelian Asset Management LLP, with participation from other investors. The round marks a significant follow-on to the company’s earlier $4 million fundraise in 2022, which was backed by Kotak Alternate Asset Management, RVCF Ventures and Unicorn India Ventures.
Use of Proceeds
FutureCure Health said the fresh capital will be used to expand access to diagnosis and treatment of vertigo, an area that remains underserved despite its high prevalence. The company plans to scale its specialised care model across hospitals and clinics in India and overseas.
Company Background
Founded in 2015 by Rajneesh Bhandari and Anita Bhandari, FutureCure operates NeuroEquilibrium, its wholly owned subsidiary focused on vertigo and dizziness diagnostics and rehabilitation. Unlike symptom-led treatment models, NeuroEquilibrium emphasises identifying the underlying cause of vertigo, whether linked to the inner ear, brain or balance pathways, enabling targeted and long-term care.
Technology-Led Care Model
NeuroEquilibrium integrates advanced diagnostic systems with cloud-based platforms to deliver specialised neuro-otology care beyond major urban centres. The model is designed to address the global shortage of specialists by enabling scalable, technology-assisted diagnostics.
Scale and Reach
According to the company, NeuroEquilibrium operates more than 300 clinics across India and 16 other countries. It has supported diagnosis and treatment for over 150,000 patients through partnerships with hospitals, ENT clinics and neurology centres.
Strategic Direction
As it scales, the platform is also expanding into adjacent chronic lifestyle conditions such as migraine and diabetes, using precision diagnostics to improve outcomes and broaden access to super-speciality healthcare.
Keep building. Keep learning. Keep growing with StartupByDoc.